Year	Study	Country	Clinical Trial #	Sponsor(s)	Treatment	N	Male	Age Min	Age Med	Age Max	ECOG 0	ECOG 1	ECOG 2	ECOG 3	KPS 100	KPS 90	KPS 80	KPS 70	KPS 60	KPS 50	Stages II	Stages III	Stages IV	Prior Treatments C+R	Prior Treatments R	Prior Treatments C	Results ORR	Results CR	Progression-Free Survival median	PFS 6-mo	PFS 12-mo	PFS 18-mo	Overall Survival median	OS 6-mo	OS 12-mo	OS 18-mo	OS 24-mo	Links		Subgroups Benefitted
1999	Storniolo AM, et al.				Gemcitabine	3023	56%		65						8	28	26	21	9	6	7	13	80	NR		37%	12%	1%	2.7	NR	NR	NR	4.8	41%	15%	2%	NR	PubMed	PDF	
1997	**Burris HA, et al.**				**Gemcitabine**	**63**	**54%**	**37**	**62**	**79**					**0**	**30**			**70**		**14**	**14**	**72**	N		N	**24%**	**0%**	**2.3**	**22%**	**9%**	**0%**	**5.7**	**46%**	**18%**	**5%**	**NR**	PubMed	PDF	
					5-FU	63	54%	36	61	77					0	32			68		8	16	76				5%	0%	0.9	5%	5%	NR	4.4	31%	2%	NR	NR			
2002	Berlin, et al.		?		Gem/5-FU	160	52%	28	65	84											0	11	89				7%	NR	3.4	NR	NR	NR	6.7	NR	NR	NR	NR	PubMed		
					Gemcitabine	162	53%	36	62	84											0	10	90				6%	NR	2.2	NR	NR	NR	5.4	NR	NR	NR	NR			
2002	Colucci G, et al.		?		Gem/Cisplatin	53	35%	37	64	82											19	19	62	N		N	26%	0%	4.6	28%	8%	2%	6.9	NR	NR	NR	NR	PubMed	PDF	
					Gemcitabine	54	50%	43	63	75											20	26	54				9%	2%	1.8	18%	5%	0%	4.6	NR	NR	NR	NR			
2002	Ducreux M, et al. (France)	Europe	NCT00003029	EORTC	5-FU/Cisplatin	104	67%		60		29	61	39									6	94	N		N	12%	NR	2.4	19%	10%	3%	3.7	38%	17%	9%	5%	PubMed	PDF	
					5-FU	103	67%		60		28	58	17									12	88				0%	0%	1.9	4%	0%	0%	3.4	28%	9%	5%	2%			
2002	Bramhall SR, et al.	Europe, NA		British Biotech Pharmaceuticals	Gem/Marimastat	120	69%	32	62	83											18	12	70	N		N	16%	1%	3.0	29%	9%	7%	5.4	46%	17%	9%	NR	PubMed	PDF	
					Gem/Placebo	119	71%	37	62	85											15	12	73				11%	0%	3.2	23%	10%	6%	5.4	42%	18%	9%	NR			
2002		USA	NCT00033735	MGI Pharma	5-FU	~233													0	0							NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	News		Stopped as 5-FU arm had better than expected OS benefit
					Irofulven	~177													0	0							NR	NR	NR	NR	NR	NR	NR	NR	NR			
2003	Moore MJ, et al.	Canada, USA		Bayer Corporation	BAY 12-9566	138	59%		65		20	62	18	0							0	38	62		4%	N	1%	NR	1.7	9%	NR	NR	3.7	27%	10%	NR	NR	PubMed	PDF	Ended at 2nd interim analysis for futility
					Gemcitabine	139	55%		66		24	55	20	0							0	35	65		5%	N	5%	NR	3.5	27%	12%	NR	6.6	56%	25%	NR	NR			
2004	Van Cutsem E, et al.	Europe, NA	NCT00005648	Johnson & Johnson	Gem/Tipifarnib	341	57%	29	61	89												24	76	Y		N	6%	NR	3.7	NR	NR	NR	6.3	53%	27%	NR	NR	PubMed	PDF	Locally advanced; Developed for HRAS mutated tumors
					Gem/Placebo	347	58%	30	62	88												23	77				8%	NR	3.6	NR	NR	NR	6.0	49%	24%	NR	NR			
2004	Jabobs, AD, et al.	USA	NCT00005869	Astex Pharmaceuticals	Rubitecan	198	53%	37	64	86											1	7	91	Y	Y	Y	6%	1%	1.9	22%	4%	NR	3.6	69%	36%	25%	17%	ASCO	PDF	
					Best Choice	211	55%	31	61	84											3	3	93				0%	0%	1.6	9%	2%	NR	3.1	60%	31%	22%	18%			
2004	Rocha Lima CM, et al.		?		Gem/Irinotecan	173	57%	38	63	81											0	15	82	Y		N	16%	2%	3.5	31%	11%	3%	6.3	NR	21%	NR	NR	PubMed	PDF	
					Gemcitabine	169	53%	32	60	82											0	13	81				4%	0%	3.0	23%	8%	7%	6.6	NR	22%	NR	NR			
2005	Oettle H, et al.	Asia, Australia, Europe NA, SA	NCT00035035	Eli Lilly and Company	Gem/Pemetrexed	283	60%	27	63	82											10	91	N		N	15%	NR	3.9	NR	NR	NR	6.2	52%	21%	10%	NR	PubMed	PDF	
					Gemcitabine	282	54%	28	63	82											9	90				7%	NR	3.3	NR	NR	NR	6.3	52%	20%	10%	NR			
2005	Louvet C, et al.	France	NCT00075452	Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)	Gem/Oxaliplatin	157	60%	35	61	77											0	30	70	N		N	27%	NR	5.8	47%	14%	7%	9.0	68%	35%	18%	12%	PubMed	PDF	
					Gem	156	53%	22	60	75											0	30	68				17%	NR	3.7	29%	13%	6%	7.1	61%	28%	12%	7%			
2005	Hawkins R, et al.		NCT00044031	Cancer Advances Inc.	Gem/Insegia	199													0	0							21%	NR	3.9	NR	NR	NR	5.9	NR	NR	NR	NR	News		patients with 16U antibody response (OS=8.7m)
					Gem/Placebo	184													0	0							23%	NR	3.9	NR	NR	NR	6.6	NR	NR	NR	NR			
2006		USA	NCT00088660	Therion Biologics	PANVAC-VF	~125							0	0									100				NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	News		Did not meet primary efficacy endpoint of OS improvement
					Best Supportive Care	~125							0	0									100				NR	NR	NR	NR	NR	NR	NR	NR	NR	NR			
2006	Heinemann V, et al.	Germany	?		Gem/Cisplatin	98	65%	37	64	82												20	80	N			12%	0%	5.3	43%	10%	4%	7.5	62%	27%	20%	11%	PubMed	PDF	Locally advanced; KPS > 90
					Gemcitabine	97	62%	43	66	85												21	79				9%	0%	3.1	30%	6%	4%	6.0	50%	24%	11%	7%			
2006	Abou-Alfa GK, et al.	NA			Gem/Exatecan	175	53%	36	63	85												21	79	N		5-FU	7%	1%	3.6	36%	NR	NR	6.7	54%	23%	NR	NR	PubMed	PDF	None identified
					Gemcitabine	174	57%	30	62	84												22	78				6%	1%	3.7	29%	15%	NR	6.2	52%	21%	NR	NR			
2006	Stathopoulos, et al.		?		Gem/Irinotecan	71	39%	31	64	84		87		13	0						0	22	78	0%	0%	0%	15%	0%	2.8	NR	NR	NR	6.4	59%	24%	6%	3%	PubMed	PDF	
					Gemcitabine	74	42%	44	64	83		86		14	0						0	14	86	0%	0%	0%	10%	4%	2.9	NR	NR	NR	6.5	50%	22%	13%	7%			
2007	Herrmann R, et al.	Europe	NCT00030732	Swiss Group for Clinical Cancer Research	Gem/Capecitabine	160	54%	27	62	83												20	80	Y		N	10%	1%	4.3	37%	13%	7%	8.4	59%	32%	14%	7%	PubMed	PDF	KPS > 90
					Gemcitabine	159	53%	36	62	84												21	79				8%	0%	3.9	35%	6%	2%	7.2	61%	30%	9%	2%			
2007	**PA.3**	**Africa, Asia, Australia Europe, NA, SA**	**NCT00026338**	**NCIC Clinical Trials Group**	**Gem/Erlotinib**	**282**	**48%**	**38**	**64**	**84**	**30**	**51**	**19**	**0**							0	24	76	**8%**		**7%**	**9%**	**NR**	**3.8**	**32%**	**10%**	**NR**	**6.2**	**53%**	**23%**	**6%**	**NR**	PubMed	PDF	developed grade ≥2 skin rash during treatment
					Gem/Placebo	280	57%	36	64	92	30	52	18	0										9%		8%	8%	NR	3.6	25%	4%	NR	5.9	49%	17%	4%	NR			
2009	Eckhardt SG, et al.		?	Johnson & Johnson	Gem/Tipifarnib	124	64%	35	63	81	30	56	15	0								29	71		2%	0%	NR	NR	2.3	26%	10%	0%	6.7	NR	NR	NR	NR	PubMed	PDF	Developed for HRAS mutated tumors
					Gem/Placebo	120	59%	35	60	86	31	54	15	0								27	73		7%	0%	NR	NR	3.0	26%	5%	0%	7.4	NR	NR	NR	NR			
2009	Buanes T, et al.	Australia, Europe, USA	NCT00358566	Pharmexa A/S	Gem/GV1001	183	63%		61		37	63	0	0								21	79	N			NR	NR	1.9	NR	NR	NR	5.9	NR	NR	NR	NR	ASCO		Terminated, no benefit
					Gem	182	59%		61		34	66	0	0								22	78				NR	NR	3.7	NR	NR	NR	7.3	NR	NR	NR	NR			
2009	Cutsem EV, et al.	Africa, Asia, Australia Europe, NA, SA	NCT01214720	Hoffmann-La Roche	Gem/Erl/Bevacizumab	306	57%	20	62	85					23	39	25	9	4	0	0	0	100	3%		Y	14%	1%	4.6	36%	8%	3%	7.1	60%	23%	10%	NR	PubMed	PDF	Not determinable
					Gem/Erl	301	62%	33	61	85					24	40	24	9	4	0	0	0	100	2%			9%	0%	3.6	22%	4%	0%	6.0	52%	19%	12%	NR			
2009	Poplin E, et al.	USA, S Africa	NCT00058149	Eastern Cooperative Oncology Group	Gem/Oxaliplatin	272	46%	29	63	96	27	62	11	0								11	89	8%		4%	9%	0%	2.7	26%	7%	3%	5.7	48%	21%	11%	6%	PubMed	PDF	
					Gemcitabine (FDR)	277	58%	36	61	87	31	57	12	0								11	89	8%		6%	10%	0%	3.5	25%	6%	1%	6.2	51%	21%	10%	6%			
					Gemcitabine	275	56%	43	66	85	34	54	12	0								10	90	8%		6%	6%	0%	2.6	17%	5%	1%	4.9	41%	16%	9%	4%			
2009	Cunningham D, et al.	UK	NCT00032175	Cancer Research UK	Gem/Capecitabine	267	60%	37	62	82	25	56	19	0								30	70	0%		0%	19%	3%	5.3	40%	14%	5%	7.1	59%	24%	13%	5%	PubMed	PDF	
					Gemcitabine	266	58%	26	62	83	21	61	18	0								29	71	0%		0%	12%	0%	3.8	31%	8%	2%	6.2	50%	22%	7%	3%			
2009	Ciuleanu TE, et al.	Asia, Europe, NA, SA	NCT00099294	Threshold Pharmaceuticals	Glufosfamide	148														0	0	0	100		100%	NR	NR	NR	NR	NR	NR	3.5	NR	NR	NR	NR	PubMed		diabetic patients taking glucose-lowering agents (sufonylureas)
					Best Supportive Care	155														0	0	0	100		100%	NR	NR	NR	NR	NR	NR	2.8	NR	NR	NR	NR			
2010	FFDC 0301	France	NCT00303758	Federation Francophone de Cancerologie Digestive	5-FU/LV/Cis, Gem	102	64%	40	62	84	27	50	21	0											1%	0%	NR	3%	3.4	NR	NR	NR	6.7	NR	29%	NR	8%	PubMed	PDF	
					Gem, 5-FU/LV/Cis	100	64%	39	65	81	30	53	14	0											2%	3%	NR	4%	3.5	NR	NR	NR	8.0	NR	33%	NR	4%			
2010	Kindler HL, et al.	USA	NTC00088894	NCI	Gem/Bevacizumab	302	58%	26	64	88	37	51	12	0								16	84	11%			13%	1%	3.8	32%	10%	4%	5.8	49%	21%	7%	3%	ASCO	PDF	None identified
					Gem/Placebo	300	51%	35	65	86	38	52	10	0								15	85				10%	1%	2.9	25%	6%	3%	5.9	51%	20%	8%	4%			
2010	Philip PA, et al.	USA, Canada	NCT00075686	NCI Cancer and Leukemia Group B	Gem/Cetuximab	372	51%		64													21	79	Y		Y	12%	0%	3.4	NR	NR	NR	6.3	52%	20%	9%	4%	PubMed	PDF	
					Gemcitabine	371	54%		64													22	79				14%	0%	3.0	NR	NR	NR	5.9	49%	19%	9%	5%			
2010	GIP-1	Italy	NCT00813696	Istituti Tumori Giovanni Paolo II	Gem/Cisplatin	201	62%	35	63	75												3	12	85			N	13%	2%	3.8	33%	15%	8%	7.2	58%	31%	17%	9%	PubMed	PDF	None identified
					Gemcitabine	199	57%	37	63	75												5	12	83				10%	1%	3.9	33%	13%	7%	8.3	62%	34%	19%	13%			
2011	Kindler HL, et al.	Africa, Asia, Australia Europe, NA, SA	NCT00471146	Pfizer	Gem/Axitinib	314	61%	34	61	84	47	52	0	0							**0**	24	76	3%		4%	5%	NR	4.4	33%	0%	0%	8.5	63%	NR	NR	NR	PubMed	PDF	Ended for futility
					Gem/Placebo	316	60%	35	62	89	50	49	0	0							**0**	24	76	4%		4%	2%	NR	4.4	35%	0%	0%	8.3	66%	NR	NR	NR			
2011	**PRODIGE 4/ ACCORD 11**	**France**	**NCT00112658**	**UNICANCER**	**FOLFIRINOX**	**171**	**62%**	**25**	**61**	**76**	**37**	**62**	**1**	**0**							**0**	**0**	**100**	N		N	**32%**	**1%**	**6.4**	**53%**	**12%**	**3%**	**11.1**	**76%**	**48%**	**19%**	**NR**	PubMed	PDF	**all subgroups**
					Gemcitabine	171	61%	34	61	75	39	61	0	0							0	0	100				9%	0%	3.3	17%	4%	0%	6.8	58%	21%	6%	NR			
2012	BAYPAN	France	NCT00541021	Institut Paoli-Calmettes	Gem/Sorafinib	52	58%	42	61	85	34	55	11	0								17	83	N		N	23%	NR	3.8	33%	6%	NR	8.0	65%	28%	NR	NR	PubMed	PDF	None identified
					Gemcitabine	52	62%	40	64	82	35	59	6	0								23	77				19%	NR	5.7	48%	6%	NR	9.2	72%	33%	NR	NR			
2013	**IMPACT**	**Asia, Australia, Europe NA**	**NCT00844649**	**Celgene Corporation**	**Gem/Abraxane**	**431**	**57%**	**27**	**62**	**86**					**16**	**42**	**35**	**7**	**0**	**0**	**0**	**0**	**100**	N		N	**23%**	**NR**	**5.5**	**44%**	**16%**	**5%**	**8.7**	**66%**	**35%**	**16%**	**10%**	PubMed	PDF	**age < 65; CA19-9 ≥ 59; NLR ≤ 5; KPS 70-80; head tumor; liver mets**
					Gemcitabine	430	60%	32	63	88					16	46	30	8	0	0	0	0	100				7%	0%	3.7	25%	9%	9%	6.6	55%	22%	9%	5%			
2013	Heinemann V, et al.	Germany	NCT00440167	Roche Pharma AG	Gem/Erl, Xeloda	143	57%	32	65	78					59			35		0	0	15	85	N		N	NR	NR	3.2	NR	NR	NR	6.2	NR	NR	NR	NR	PubMed	PDF	wild KRAS
					Xeloda/Erl, Gem	131	63%	38	63	75					60			33		0	0	17	83				NR	NR	2.2	NR	NR	NR	6.9	NR	NR	NR	NR			wild KRAS
2013	GEST	Japan, Taiwan	?	Taiho Pharmaceutical TTY Biopharm	Gem/S-1	275	58%				64	36	0	0								25	75				29%	1%	5.7	48%	20%	10%	10.1	77%	41%	21%	15%			Locally advanced; ECOG 1; Asians
					Gemcitabine	277	61%		65		65	35	0	0								24	76	N		N	13%	0%	4.1	30%	9%	4%	8.8	67%	35%	19%	9%	PubMed	PDF	
					S-1	280	61%				64	36	0	0								24	76				21%	0%	3.8	27%	7%	3%	9.7	68%	39%	20%	13%			
2013	VANILLA	Asia, Europe, NA, SA	NCT00574275	Sanofi	Gem/Aflibercept	271								0							0	0	100				NR	NR	3.7	NR	NR	NR	6.5	NR	NR	NR	NR	PubMed		Study Terminated for futility
					Gem/Placebo	275								0							0	0	100				NR	NR	3.7	NR	NR	NR	7.8	NR	NR	NR	NR			
2014	**NAPOLI-1**	**Asia, Australia, Europe NA, SA**	**NCT01494506**	**Merrimack Pharmaceuticals**	**MM-398/5-FU/LV**	**117**	**59%**	**41**	**63**	**81**						**56**		**44**		**0**	**0**	**0**	**0**	**100**		**100%**	**16%**	**NR**	**3.1**	**28%**	**6%**	**0%**	**6.1**	**53%**	**24%**	**NR**	**NR**			KPS 70-80; albumin < 4.0; age ≤ 65; tail tumor
					MM-398	151	58%	31	65	87						56		44		0	0	0	0	100	N	100%		6%	NR	NR	NR	NR	4.9	39%	12%	3%	NR	PubMed	PDF	
					5-FU/LV	119	56%	34	62	80						56		44		0	0	0	0	100		100%		1%	NR	1.5	11%	5%	NR	4.2	38%	17%	NR	NR			
2014	TeloVac	UK	NCT00425360	Royal Liverpool University Hospital	Gem/Cap/GV1001	354	55%	57	63	59	29	60	11	0								31	69				16%	NR	6.6	51%	22%	12%	8.4	63%	32%	16%	9%			
					Gem/Cap, GV1001	350	58%	58	64	69	29	60	11	0								30	70	Y		Y	9%	NR	4.5	32%	10%	4%	6.9	59%	25%	13%	7%	PubMed	PDF	None identified
					Gem/Cap	358	58%	55	62	69	29	60	11	0								31	69				18%	NR	6.4	51%	22%	11%	7.9	63%	34%	18%	13%			
2014		Germany	NCT00561990	Oncoscience AG	Gem/Nimotuzumab	93	66%								20	46	24	9	0	0	0	26	74			N	9%	0%	5.3	*42%*	22%	NR	8.6	*58%*	34%	17%	NR	PubMed	PDF	Wildtype KRAS better OS
					Gem/Placebo	93	59%								31	41	22	6	0	0	0	17	84				9%	0%	3.1	*28%*	10%	NR	6.0	50%	19%	9%	NR			
2015	GAMMA	Asia, Australia, Europe NA, SA	NCT01231347	Amgen	Gem/Ganitumab (12)	318	50%	36	62	85	44	55	1	0							0	0	100				16%	NR	3.6	*26%*	*4%*	NR	7.0	*57%*	*26%*	*7%*	NR			IGF-1+; IGF-2+; IGFBP-3+; IGFBP-2-
					Gem/Ganitumab (20)	160	53%	31	62	81	44	56	0	0							0	0	100	N		N	15%	NR	3.7	*26%*	*5%*	NR	7.1	*63%*	*25%*	NR	NR	PubMed		IGF-1+; IGF-2+; IGFBP-3+; IGFBP-2-
					Gem/Placebo	322	58%	36	63	83	43	57	0	0							0	0	100				10%	NR	3.7	*24%*	*2%*	NR	7.2	*58%*	*27%*	*13%*	NR			halted early when unlikely to meet OS objective
2015	Deplanque G, et al.	Europe, USA	NCT00789633	AB Science	Gem/Masitinib	175	50%	36	63	84	38	62	0	0									86			0%	NR	NR	NR	NR	NR	NR	7.7	NR	NR	NR	NR	PubMed	PDF	in pain; ACOX1 overexpression in blood
					Gem/Placebo	178	58%	31	62	79	35	65	0	0												0%	NR	NR	NR	NR	NR	NR	7.0	NR	NR	NR	NR		Supp	did *poorly*: in pain, ACOX1 overexpressed in blood
2015	ONTRAC	USA, India, Hungary, Russia Ukraine	NCT01360853	Onconova Therapeutics, Inc.	Gem/Rigosertib	106	65%	29	63	83	26	67	7	0							0	0	100	N	N	N	19%	0%	3.4	*25%*	5%	0%	6.1	51%	*15%*	NR	NR		PDF	
					Gemcitabine	54	57%	30	62	87	24	74	2	0							0	0	100	N	N	N	13%	0%	3.4	*29%*	4%	0%	6.4	50%	*20%*	NR	NR			
2016	MAESTRO	Germany, USA	NCT01746979	Threshold Pharmaceuticals	Gem/TH-302	346	55%							0						0							NR	NR	5.5	NR	NR	NR	8.7	NR	34%	NR	NR	ASCO		Asian patients showed much better OS
					Gem/Placebo	347	52%							0						0							NR	NR	3.7	NR	NR	NR	7.6	NR	30%	NR	NR		News	
2016	PANCRIT-1	Europe, NA	NCT01956812	Immunomedics, Inc.	Gem/IMMU-107	~167													0	0	0	0	100				NR	NR	NR	NR	NR	NR	NR	NR	NR	NR			Study Terminated (futility)
					Gem/Placebo	~167													0	0	0	0	100				NR	NR	NR	NR	NR	NR	NR	NR	NR	NR			
2016	Janus 1	Asia, Australia, Europe, NA	NCT02117479	Incyte Corporation	Cap/Ruxolitinib	161	59%	26	58	91	22	66	12	0							0	0	100			100%	4%	0%	1.4	6%	0%	NR	2.9	21%	5%	NR	NR	PubMed	PDF	Halted Feb 2016 for lack of efficacy
					Cap/Placebo	160	60%	28	67	83	17	68	15	0							0	0	100			100%	2%	0%	1.4	6%	NR	NR	3.1	20%	NR	NR	NR			
2016	PANCREOX	Canada	NCT01121848	Sanofi	mFOLFOX	54	57%	38	65	82	13	76	11	0							0	7	93			1	13%	NR	3.1	35%	20%	NR	6.1	50%	23%	NR	NR	ASCO	Text	PFS: age ≥70
					5-FU/LV	54	43%	48	67	78	19	76	6	0							0	6	94				9%	NR	2.9	39%	13%	NR	9.9	66%	41%	NR	NR			
2017		USA	NCT02101021	Sierra Oncology, Inc.	Gem/Abr/Momelotinib	25	68%																				NR	NR	NR	NR	NR	NR	NR	NR	NR	NR			Study Terminated
					Gem/Abr/Placebo	0	NA																				NR	NR	NR	NR	NR	NR	NR	NR	NR	NR			
2017	Lee, Hee Seung	S. Korea	?		Gem	101	54%	43	64	85		83		17							9	19	72			N	18%	0%	5.3	NR	NR	NR	7.5	NR	NR	NR	NR	PubMed	PDF	
					Gem/Capecitabine	103	58%	37	64	80		91		9							6	21	73				44%	0%	6.2	NR	NR	NR	10.3	NR	NR	NR	NR			
2018	PANCREADOGREL	France	NCT02404363	Assistance Publique - Hôpitaux de	Clopidogrel	~19							0	0							0						NR	NR	NR	NR	NR	NR	NR	NR	NR	NR			Study Terminated (recruitment problems)
					Placebo	~19							0	0							0						NR	NR	NR	NR	NR	NR	NR	NR	NR	NR			
Active	Chen, Li-Tzong	Asia	NCT02043288	Orient Europharma Co., Ltd.	Gem/NC-6004	~200							0	0							0			N	N	N	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	Phase 1	PDF	
					Gemcitabine	~200							0	0							0						NR	NR	NR	NR	NR	NR	NR	NR	NR	NR			
2019	POLO	Asia, Europe, NA	NCT02184195	AstraZeneca	Olaparib	92	58%	37	57	84	71	27	0	0							0	0	100			Plat	23%	3%	7.4	53%	34%	28%	18.9	87%	70%	54%	38%	PubMed		germline BRCA1/2 mutations that responded to platinum chemo
					Placebo	62	50%	36	57	75	61	37	0	0							0	0	100			Plat	12%	0%	3.8	23%	15%	10%	18.1	93%	66%	51%	35%			
2019	RESOLVE	USA, Europe, Asia	NCT02436668	Pharmcyclics LLC	Gem/Abr/Ibrutinib	211							0	0						0	0	0	100	N	N	N	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR			Did not improve PFS or OS
					Gem/Abr/Placebo	213							0	0						0	0	0	100				NR	NR	NR	NR	NR	NR	NR	NR	NR	NR			